Recombinant Human KiSS-1 receptor (KISS1R)

What is the relationship between the KISS1 gene, kisspeptins, and KISS1R?

The KISS1 gene encodes KISS1, a protein that is rapidly processed in serum into smaller biologically active peptides called kisspeptins (KPs). KISS1 and the KPs signal via the G-protein coupled receptor KISS1R. While initially recognized for regulating reproductive neuroendocrine functions, their first reported role was metastasis suppression in melanoma. These molecules now show context-dependent roles across various cancer types .

What are the primary signaling pathways activated by KISS1R?

KISS1R activation by kisspeptin stimulates phosphatidylinositol turnover and arachidonic acid release through activation of the mitogen-activated protein kinases and extracellular kinases 1/2 pathways. This signaling is critical for its biological functions in both normal physiology and pathological conditions . In experimental settings, total inositol phosphate production is often used as a marker of KISS1R signaling, with levels typically peaking after 2 hours of stimulation before declining as the receptor desensitizes .

How does KISS1R trafficking occur following ligand binding?

KISS1R undergoes time-dependent internalization upon kisspeptin stimulation, but importantly, most internalized receptors are recycled back to the membrane rather than degraded. Experimental tracking shows approximately 50% of receptors are internalized after 15 minutes of stimulation, and approximately 80% are internalized after 60 minutes, with only about 20% remaining on the cell surface . This dynamic recycling pattern, rather than degradation, explains the receptor's persistent membrane localization observed in confocal imaging studies.

How does KISS1R expression vary across different cancer types?

KISS1R shows remarkable context-dependent expression patterns across cancer types:

Why does KISS1R function as both a tumor suppressor and promoter?

KISS1, KPs, and KISS1R represent a relatively rare group of molecules exhibiting dual roles in cancer. While they act as suppressors of tumorigenesis and metastasis in many cancers, they function as promoters in breast and liver cancer . This duality highlights the importance of studying cancer in context. The relationship between these molecules and a given cancer is complex and affected by multiple factors such as:

• The specific microenvironment

• Steroid receptor status of cancer cells

• Stage of cancer progression

• Tissue-specific signaling pathways

How does KISS1R expression change during cancer progression?

In several cancer types including pancreatic, ovarian, and colorectal cancer, researchers have observed that KISS1/KISS1R expression is high in early stages but progressively diminishes with cancer advancement . This pattern suggests a complex regulatory mechanism that changes during disease progression. For instance, in pancreatic cancer, tumors negative for both KP-54 and KISS1R expression were significantly larger than positive tumors, and KP-54 positive tumors showed less frequent recurrence .

What techniques are most effective for studying KISS1R trafficking?

Several complementary techniques have proven valuable for investigating KISS1R trafficking:

• Radioligand binding assays: Using 125I-kisspeptin to track receptor internalization by measuring the relative distribution of receptors in membrane and intracellular fractions at specific time points .

• Confocal microscopy: Employing fluorescently-tagged KISS1R (such as CFP-KISS1R) to visualize receptor localization and trafficking. This approach can detect colocalization with membrane markers (like Na+/K+ATPase) to confirm surface expression or internalization .

• Surface biotinylation: Labeling surface proteins to distinguish between membrane-bound and internalized receptors.

• Calcium flux assays: Measuring functional desensitization as an indirect measure of receptor trafficking.

How can researchers investigate KISS1R degradation mechanisms?

KISS1R degradation pathways can be studied through several approaches:

• Proteasome vs. lysosome inhibition: Overnight treatment with proteasome inhibitors increases KISS1R protein levels by approximately 24-fold, while lysosome inhibitors show no effect, indicating proteasomal rather than lysosomal degradation .

• Pulse-chase experiments: To track the fate of newly synthesized receptors.

• Mutational analysis: Comparing degradation rates between wild-type and mutant receptors, such as the Arg386Pro mutant which shows decreased degradation and prolonged responsiveness to kisspeptin .

• Colocalization studies: Using confocal imaging to assess receptor colocalization with proteasomal or lysosomal markers following stimulation.

What approaches are effective for studying KISS1R as a cancer biomarker?

For investigating KISS1R as a cancer biomarker, several approaches have proven valuable:

• In vitro co-culture systems: Studying myeloma cells with mesenchymal stem cells (MSCs) has revealed KISS1R upregulation on MSCs when co-cultured with cancer cells .

• Fluorescently-labeled kisspeptin: Conjugating kisspeptin with fluorescent dyes enables visualization of binding to both cancer cells and microenvironment components in vitro and in vivo .

• In vivo imaging: Injecting conjugated kisspeptin into mice with myeloma bone lesions shows increased fluorescence in tumor-burdened limbs compared to controls, demonstrating potential as an imaging biomarker .

• Quantitative PCR and immunohistochemistry: For measuring KISS1/KISS1R expression levels and localization patterns in clinical samples .

How does the Arg386Pro mutation affect KISS1R function?

The Arg386Pro mutation in KISS1R contributes to human central precocious puberty by prolonging receptor responsiveness to kisspeptin. Research has revealed that this mutation does not affect the rate of receptor trafficking (internalization or recycling); instead, it decreases receptor degradation . This results in a net increase of mutant receptors recycled back to the plasma membrane after stimulation. Key findings show:

• Both wild-type and Arg386Pro mutant KISS1R internalize upon stimulation and mostly recycle back to the membrane

• The mutation does not affect the relative distribution between membrane and internalized fractions

• Total Arg386Pro KISS1R is substantially increased compared to wild-type after 120 minutes of kisspeptin stimulation

• Blocking recycled receptor detection eliminates the increased responsiveness of the mutant

What is the significance of KISS1R in the tumor microenvironment?

KISS1R expression extends beyond cancer cells to include cells of the tumor microenvironment, offering unique research and therapeutic opportunities:

• In multiple myeloma, KISS1R is upregulated on mesenchymal stem cells (MSCs) and osteoprogenitor cells (OPCs) when co-cultured with myeloma cells .

• This expression pattern enables potential targeting of both malignant cells and the supporting microenvironment.

• Beyond autocrine mechanisms, paracrine signaling between kisspeptin-expressing tumor cells and KISS1R-expressing stromal cells has been suggested .

• This interaction is particularly relevant in myeloma where tumor-microenvironment interactions drive tumor progression and bone disease.

How does estrogen receptor signaling interact with KISS1/KISS1R expression?

Estrogen receptor signaling appears to negatively regulate KISS1/KISS1R expression in multiple contexts:

• In breast cancer research, treatment of ERα-positive MCF7 and T47D cells with tamoxifen (a selective estrogen receptor modulator) stimulates KISS1/KISS1R expression .

• This suggests that ERα signaling normally downregulates KISS/KISS1R levels in breast tissue.

• This negative regulation by ERα is well-documented in ARC KISS1 neurons in the hypothalamus .

• The relationship between ER status and KISS1/KISS1R expression helps explain observed differences in KISS1R function across breast cancer subtypes.

How can researchers interpret contradictory data on KISS1R in liver cancer?

Studies on KISS1/KISS1R in hepatocellular carcinoma (HCC) have produced contradictory findings that require careful interpretation:

• Ikeguchi et al. showed KISS1 and KISS1R mRNA overexpression (22% and 43%, respectively) in HCC samples, positively associated with disease progression and poor survival .

• Schmid et al. reported that elevated KP-54 expression correlated with worsened clinical outcomes in HCC patients who underwent liver transplantation .

• In contrast, Shengbing et al. reported that KISS1 protein expression is lost in HCC, suggesting tumor suppressive roles, and found a negative association between KISS1 and MMP-9 .

These contradictions may reflect differences in:

• Detection methods (mRNA vs. protein)

• Sample timing (pre/post-treatment)

• Disease subtypes or stages

• Concurrent pathway activations

What methodological approaches can help resolve data inconsistencies?

To address contradictory findings in KISS1R research, consider these methodological approaches:

• Comprehensive expression analysis: Measure both mRNA and protein levels simultaneously in the same samples.

• Cell-specific analysis: Use techniques like single-cell RNA sequencing or laser capture microdissection to distinguish expression in cancer cells versus stromal cells.

• Pathway activation assessment: Evaluate downstream signaling pathway activation alongside receptor expression.

• Longitudinal sampling: Collect samples at multiple disease stages from the same patients when possible.

• Standardized reporting: Include detailed patient characteristics, treatment history, and methodology descriptions to facilitate comparison across studies.

How can KISS1R be developed as a diagnostic imaging biomarker?

KISS1R shows promise as an imaging biomarker, particularly for cancers with significant microenvironment involvement:

• In multiple myeloma, fluorescently-labeled kisspeptin binds to both myeloma cells and mesenchymal stem cells in co-culture .

• In vivo studies show that conjugated kisspeptin injected into mice with myeloma bone lesions results in increased fluorescence in tumor-burdened limbs compared to controls .

• Future research should focus on:

  • Optimizing kisspeptin conjugates for clinical imaging

  • Developing dual-targeting approaches to improve specificity

  • Exploring PET or SPECT tracers based on kisspeptin analogs

  • Correlating imaging findings with disease progression and treatment response

What therapeutic strategies could target the KISS1/KISS1R system?

Based on the dual role of KISS1/KISS1R in cancer, several therapeutic strategies merit investigation:

• Cancer-specific modulation: Developing agonists for cancers where KISS1R acts as a suppressor, and antagonists where it functions as a promoter.

• Targeted drug delivery: Using kisspeptin conjugates to deliver cytotoxic agents specifically to KISS1R-expressing tumors and their microenvironment.

• Combination approaches: Pairing KISS1R modulators with inhibitors of downstream signaling pathways like PI3K/AKT and Ras/ERK, which are often dysregulated in carcinomas and linked to drug resistance .

• Microenvironment targeting: Exploiting KISS1R expression on stromal cells to disrupt tumor-microenvironment interactions that promote cancer progression.

How might KISS1R signaling interact with drug resistance mechanisms?

Recent findings suggest important connections between KISS1R and drug resistance:

• KISS1R signaling induces drug resistance in triple-negative breast cancer (TNBC) cells by upregulating the efflux drug transporter breast cancer resistance protein (ABCG2) .

• KISS1R activation leads to increased expression and activation of the tyrosine kinase AXL, which is associated with drug resistance .

• KISS1R engages with PI3K/AKT and Ras/ERK pathways, which are the most dysregulated signaling cascades in human carcinomas related to tumor drug resistance, survival, and proliferation .

• Future research should investigate whether KISS1R inhibition could resensitize resistant tumors to conventional therapies.